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Background: The purpose of this study was to examine the association between use of inhaled 
anticholinergics and all-cause mortality among elderly individuals with chronic obstructive 
pulmonary disease (COPD), after controlling for demographic, socioeconomic, health, functional 
status, smoking, and obesity.
Methods: We used a retrospective longitudinal panel data design. Data were extracted for 
multiple years (2002–2009) of the Medicare Current Beneficiary Survey (MCBS) linked with 
fee-for-service Medicare claims. Generic and brand names of inhaled anticholinergics were used 
to identify inhaled anticholinergic utilization from the self-reported prescription medication files. 
All-cause mortality was assessed using the vital status variable. Unadjusted group differences in 
mortality rates were tested using the chi-square statistic. Multivariable logistic regressions with 
independent variables entered in separate blocks were used to analyze the association between 
inhaled anticholinergic use and all-cause mortality. All analyses accounted for the complex 
design of the MCBS.
Results: Overall, 19.4% of the elderly Medicare beneficiaries used inhaled anticholinergics. 
Inhaled anticholinergic use was significantly higher (28.5%) among those who reported poor 
health compared with those reporting excellent or very good health (12.7%). Bivariate analyses 
indicated that inhaled anticholinergic use was associated with significantly higher rates of all-
cause mortality (18.7%) compared with nonusers (13.6%). However, multivariate analyses 
controlling for risk factors did not suggest an increased likelihood of all-cause mortality (adjusted 
odds ratio 1.26, 95% confidence interval 0.95–1.67).
Conclusion: Use of inhaled anticholinergics among elderly individuals with COPD is potentially 
safe in terms of all-cause mortality when we adjust for baseline risk factors.
Keywords: geriatrics, chronic obstructive pulmonary disease, inhaled anticholinergics, 
mortality, drug safety
Introduction
Chronic obstructive pulmonary disease (COPD) is characterized by airflow limitation 
due to chronic inflammation of the lungs.1–3 Worldwide, COPD is estimated to 
become the third leading cause of mortality and the fifth most burdensome disease.4–6 
In the United States, COPD is the fourth leading cause of morbidity and mortality.4,7 
Individuals with COPD also suffer from extensive physical and psychological 
comorbidities, which worsen their health-related quality of life and pose challenges 
to health care management,3,8 and can lead to increased risk of mortality in the elderly 
over the age of 65 years.9
Bronchodilators including long-acting and short-acting beta-2-agonists, inhaled 
anticholinergics (IAC), and combination drug therapies have been approved in the 
Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
287
ORIGINAL RESEARCH
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org./10.2147/COPD.S45166International Journal of COPD 2013:8
United States for the management of COPD.7 Traditionally, 
anticholinergics agents have been linked with an increased 
risk of fatal and nonfatal cardiovascular adverse events, 
stroke, and all-cause mortality. IAC have been shown 
to reduce the risk of adverse events due to inclusion 
of a quaternary ammonium structure which inhibits 
gastrointestinal absorption.10 However, other mechanisms 
may increase the risk of adverse events in specific subgroups. 
These include elevation of plasma IAC levels in elderly 
individuals and in those with renal impairment.11,12
Evidence regarding the safety of IAC in terms of all-cause 
mortality is inconsistent. Findings from several randomized 
controlled trials have indicated that IAC are as safe as 
placebo or active controls in terms of all-cause mortality.13,14 
Similarly, analyses of pooled data from the controlled 
trials show no statistically significant increase in risk of 
cardiovascular adverse events or all-cause mortality with 
IAC use.15–17 However, these results have been contradicted 
in a systematic review with meta-analysis which concluded 
that IAC use was associated with increased risk of composite 
cardiovascular adverse events including stroke, myocardial 
infarction, and cardiovascular death.18 Further, a nested 
case-control study reported a 34% increase in cardiovascular 
mortality and an 11% increase in all-cause mortality with 
IAC, specifically ipratropium bromide.18,19 These findings 
cannot be generalized due to methodological shortcomings 
in terms of double-counting of event data (meta-analysis) and 
not adequately accounting for baseline differences (nested 
case-control study).10,20 Subsequently, results from the four-
year UPLIFT (Understanding Potential Long-term Impacts 
on Function with Tiotropium) trial suggested that tiotropium 
was not associated with adverse events and actually reduced 
the risk of mortality.14 These findings were also supported 
by a systematic review and meta-analysis published after 
including data from the UPLIFT trial.21
None of the above-mentioned studies were specific to the 
elderly, so their findings may have limited applicability in 
the elderly population. It is reported that elderly individuals 
are not adequately represented in randomized controlled 
trials.22 Moreover, disease management in elderly individuals 
with COPD is complicated by extensive coexisting chronic 
physical and psychiatric conditions.23 For example, elderly 
individuals with COPD are at greater risk for chronic renal 
failure,24 which leads to elevated plasma IAC levels that 
may further elevate the risk of adverse events, including all-
cause mortality.11 To date, no study has rigorously examined 
the association between IAC use and all-cause mortality 
in elderly individuals with COPD. Therefore, the primary 
objective of the current study was to examine the association 
between use of IAC and all-cause mortality in elderly 
individuals with COPD. For the purposes of this study, we 
used retrospective longitudinal data from elderly Medicare 
beneficiaries seeking care in the real-world setting.
Materials and methods
Study design
We adopted a longitudinal panel design with retrospective 
observational data to analyze the association between 
use of IAC and all-cause mortality using the Medicare 
Current Beneficiary Survey (MCBS). The MCBS is a 
“nationally representative sample of aged, disabled, and 
non-institutionalized Medicare beneficiaries” with linkage 
to fee-for-service Medicare claims.25 Because individuals 
were followed for three years, we defined the baseline period 
as the first observed year of each panel. Follow-up of each 
panel for two years were used to assess mortality status, as 
discussed below.
Data source
The MCBS is a longitudinal, multipurpose survey, and is 
representative of the Medicare population in the United 
States. Medicare beneficiaries are selected using a multistage 
stratified random sampling design. Selected beneficiaries are 
followed for a period of three years. The data are continually 
collected for three rounds per year at four-month intervals. 
MCBS follows a rotating panel survey design in which each 
panel is interviewed 12 times.
The MCBS is divided into two modules, ie, “access to 
care” and “cost-and use”. The access to care module contains 
information relating to respondents’ access to medical providers 
and their satisfaction with health care for beneficiaries enrolled 
in Medicare for the entire year. In contrast with that, the cost 
and use file of the MCBS contains information on health care 
use, prescription drug use, chronic conditions, and personal 
health care practices.25 Health care expenditures and utilization 
were obtained from personal interviews conducted every four 
months as well as Medicare claims. The current study utilized 
multiple years of cost and use files linked with fee-for-service 
Medicare claims data.
Analytical sample
Individuals were considered to have diagnosed COPD if 
they had at least one inpatient visit or two outpatient visits 
for COPD based on International Classification of Diseases, 
Ninth Revision, Clinical Modification (ICD-9-CM) codes 
for chronic bronchitis (491.xx), emphysema (492.xx), 
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or   unspecified chronic airway obstruction (496.xx). Other 
inclusion criteria consisted of community-dwelling fee-for-
service Medicare beneficiaries who were over 65 years of age 
and had full-year enrollment during the baseline period.
Using the merged data from multiple years (2002–2009), 
we obtained six longitudinal panels: 2002–2004 (Panel I); 
2003–2005 (Panel II); 2004–2006 (Panel III); 2005–2007 
(Panel IV); 2006–2008 (Panel V); and 2007–2009 (Panel VI). 
The final sample consisted of 2610 Medicare beneficiaries, 
and included 424 beneficiaries in Panel I, 458 beneficiaries 
in Panel II, 406 beneficiaries in Panel III, 475 beneficiaries in 
Panel IV , 419 beneficiaries in Panel V , and 428 beneficiaries 
in Panel VI.
Key independent variable: IAC use
We identified IAC use from prescription medicine events 
files. Prescription medicine events files contain self-reported 
drug utilization at the prescription level. Two IAC are 
approved in the United States, ie, ipratropium bromide (short-
acting) and tiotropium bromide (long-acting). All generic and 
brand names for these two IAC were obtained from the US 
Food and Drug Administration register.26 These names were 
then used to identify IAC use. The first year of each panel 
was used to measure baseline characteristics as well as IAC 
use. Elderly Medicare beneficiaries who reported having at 
least one prescription for any IAC in the baseline year of 
each panel were categorized as IAC users.
Dependent variable: mortality status 
(dead versus alive)
We defined mortality status as a dichotomous variable 
(yes/no) using the “vital status” variable in the MCBS data. 
Decedent status was derived from both survey responses 
and administrative claims files.27 Medicare beneficiaries 
who died during the follow-up observation years were 
considered as decedents. For example, in the first panel 
(2002–2004), mortality status was determined using vital 
status data in follow-up years (ie, individuals who died in 
2003 or 2004).
Other independent variables
All independent variables were measured in the baseline 
period (ie, first year of observation).
Demographic variables consisted of gender (women, 
men), race (white, African American, others), age in years 
(65–69, 70–74, and $75), and metropolitan status (metro, 
not metro). Socioeconomic status included education (less 
than high school, high school, and college education), poverty 
status (,200% versus .200% of the federal poverty line), 
and prescription drug coverage (yes, no).
Coexisting chronic physical and mental health conditions 
were identified using responses to questions about whether 
beneficiaries ever had the following diseases: Alzheimer’s 
disease, arthritis, cardiovascular disease, cancer, diabetes, 
hypertension, mental illness, osteoporosis, and stroke. Based 
on three studies which analyzed multimorbidity patterns 
with respiratory diseases (one using Medicaid data28 and 
others using expert clinical reviews),29,30 separate indicator 
variables were constructed for each of the following comor-
bidities: cardiovascular/metabolic disorders (composite 
of beneficiaries with diabetes/heart disease/hypertension/
stroke); mental illness; musculoskeletal disorders (compos-
ite of beneficiaries with arthritis and/or osteoporosis) and 
other diseases (composite of beneficiaries with cancer and/
or Alzheimer’s disease). Because of the potential association 
between chronic renal failure and adverse events with use of 
IAC, we also included an indicator variable for chronic renal 
failure. Chronic renal failure was identified using the ICD-
9-CM codes in the clinical classification software31 provided 
by the Agency for Healthcare Research and Quality, ie, 585.
xx, 586, 792.5, V42.0, V45.1, V56.0–V56.32, and V56.8.
Personal health care practices were identified using smok-
ing status (current, past, never) and body mass index (BMI) 
values categorized into five different classes: underweight 
(BMI , 18.5 kg/m2); normal (BMI $ 18.5–25 kg/m2); overweight 
(BMI $ 25–30 kg/m2); and obese (BMI $ 30 kg/m2).32
Health status was measured by self-perceived general 
health. In the MCBS data, the survey respondents reported 
their physical health status as being excellent, very good, 
good, fair, or poor. For the purpose of our analyses, we 
grouped these responses as: excellent or very good health; 
good health; fair health; and poor health. A panel or cohort 
variable was used as an additional independent variable to 
adjust for time effects.
Statistical methods
Chi-square tests of independence were used to determine 
unadjusted group differences according to IAC use. In 
order to understand the independent association between 
IAC use and other variables and all-cause mortality, inde-
pendent variables were entered in separate blocks. The first 
model (model I) was an unconditional model with IAC use 
as the only independent variable. Model II adjusted for 
IAC use and coexisting conditions (mental illness, cardio-
vascular/metabolic disorders, musculoskeletal disorders, 
chronic renal failure, and other conditions). In model III, 
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we added gender, race, age, metro status, education level, 
and socioeconomic status. Model IV adjusted for perceived 
health status in addition to all the independent variables 
included in model III. Additionally, in model V, we 
included functional status, BMI category, and smoking 
status. All analyses controlled for the complex design of 
the MCBS and were conducted using survey procedures 
with Statistical Analysis System version 9.3 software (SAS 
Institute Inc, Cary, NC, USA).
Results
The final study sample obtained after applying all eligi-
bility criteria consisted of 2610 Medicare beneficiaries. 
A majority (54%) of the study sample were female, 84% 
were white, 53% were older than 75 years, 52% were mar-
ried, and 70% resided in a metropolitan area. In terms of 
socioeconomic status, 34% had no high school education 
and 42% of the sample was below 200% of the federal pov-
erty level.   Twenty-three percent of elderly individuals were 
obese and 20% were current smokers. The far right entries 
in Table 1 show the number and weighted percentages of 
beneficiaries with IAC use. The significance column reports 
the statistical significance between IAC use and beneficiary 
characteristics. Statistically significant differences in IAC 
use were observed by gender, age categories, prescription 
drug coverage, health status, functional status, and smoking 
status. IAC use was significantly higher (28.5%) among 
elderly Medicare beneficiaries who reported poor perceived 
health status as compared with those self-reporting excellent 
or very good health status (12.7%).
In our study sample, 19% of the elderly individuals 
reported IAC use in the baseline period. Table 2 summarizes 
unadjusted associations between selected beneficiary char-
acteristics and all-cause mortality. We observed a statisti-
cally significant association between IAC use and all-cause 
mortality (odds ratio [OR] 1.46, 95% confidence interval 
[CI] 1.12–1.90). Elderly Medicare beneficiaries with IAC 
use and cardiovascular/metabolic disorder had an increased 
likelihood of all-cause mortality compared with those without 
IAC use and cardiovascular/metabolic disorder (OR 1.40, 
95% CI 1.03–1.91). Medicare beneficiaries who reported 
their health status to be poor were five times more likely to 
die than those with self-reported excellent to very good health 
status (OR 5.69, 95% CI 3.79–8.53).
Multivariable logistic regressions with independent 
variables entered in separate blocks were used to examine 
the association between IAC use and all-cause mortality. 
Table 1 Description of study sample characteristics according 
to IAC use among elderly Medicare beneficiaries with COPD: 
Medicare Current Beneficiary Survey, 2002–2009
Total Percentage with 
IAC use
n wt % n wt % Sig
Gender **
  Women 1390 53.7 245 17.0
  Men 1220 46.3 255 21.7
Race
  White 2176 83.9 426 19.7
  African American 173 6.7 29 15.8
  Others 260 9.4 45 16.6
Age, years *
  65–69 557 25.2 135 23.3
  70–74 485 21.6 81 16.4
  $75 1568 53.2 284 18.4
Married
  Married 1289 51.5 243 19.1
  Not married 1320 48.5 257 19.3
Metro status
  Metro 1753 69.7 339 19.1
  Not metro 857 30.3 161 19.3
Education
  Less than high school 924 34.3 182 19.7
  High school 966 37.6 188 19.3
  College 710 28.2 130 18.7
Poverty status
  .200% FPL 1054 42.1 205 19.6
  ,200% FPL 1556 57.9 295 18.8
Prescription drug coverage *
  Yes 1973 75.8 405 20.2
  No 637 24.2 95 15.9
Health status ***
  Excellent/very good 740 29.6 94 12.7
  Good 876 33.6 160 18.4
  Fair 671 25.3 154 23.5
  Poor 310 11.5 88 28.5
Functional status (ADL) ***
  None 1556 62.0 257 16.4
  1–2 ADL 706 26.3 157 22.8
  3–6 ADL 344 11.8 85 25.7
Body mass index
  Underweight 113 4.0 29 24.9
  Normal 984 37.5 179 18.2
  Overweight 930 35.7 166 17.8
  Obese 561 22.8 123 22.1
Smoking status ***
  Current smoker 498 20.0 113 22.1
  Past smoker 1437 55.4 324 22.8
  Never smoked 671 24.6 62 8.5
Mental illness
  Yes 492 19.2 100 19.3
  No 2118 80.8 400 19.1
CMD
  Yes 2149 81.6 407 18.9
  No 459 18.4 93 20.6
(Continued )
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Discussion
This study contributes to the knowledge base on the safety 
of IAC use in terms of all-cause mortality among elderly 
Medicare beneficiaries with COPD seeking care in a real 
world-setting, with extensive controls for demographic and 
socioeconomic factors, coexisting chronic conditions, per-
sonal health care practices, and self-reported health status. 
We observed a statistically significant association between 
IAC use and all-cause mortality in the bivariate analyses. 
However, after controlling for self-reported perceived health 
status in the final model, which also included coexisting con-
ditions, and demographic, socioeconomic, and lifestyle risk 
factors, it was found that IAC use was no longer associated 
with all-cause mortality. This finding is consistent with that 
of the UPLIFT trial and other meta-analyses,14,21 and can be 
explained using the updated evidence from this field.15
Table 1 (Continued)
Total Percentage with 
IAC use
n wt % n wt % Sig
Musculoskeletal disorders
  Yes 1921 72.4 376 19.8
  No 687 27.6 123 17.5
Chronic renal failure
  Yes 195 7.1 38 18.9
  No 2415 92.9 462 19.2
Other comorbidities
  Yes 1320 49.7 262 19.2
  No 1290 50.3 238 19.1
Cohort
  2002–2004 424 15.2 79 18.2
  2003–2005 458 17.2 85 17.4
  2004–2006 406 15.8 79 19.3
  2005–2007 475 18.1 98 21.5
  2006–2008 419 16.9 84 21.4
  2007–2009 428 16.8 75 17.0
Notes:  Based  on  2610  elderly  Medicare  beneficiaries  with  COPD,  who  were 
observed between years 2002 and 2009. Asterisks represent significant association 
between inhaled anticholinergic use and beneficiary characteristics based on Chi-
square tests. ***P , 0.001; **0.001  P , 0.01; *0.01  P , 0.05.
Abbreviations: ADL, activities of daily living; COPD, chronic obstructive pulmonary 
disease; FPL, federal poverty line; IAC, inhaled anticholinergics; wt, weighted; Sig, 
significance; CMD, cardiometabolic disorders (diabetes, heart disease, hypertension 
and  stroke);  musculoskeletal  disorders,  arthritis  and  osteoporosis;  other 
comorbidities, cancer and Alzheimer’s disease. 
Even after adjusting for coexisting chronic conditions, 
we observed a statistically significant association between 
IAC use and all-cause mortality (adjusted OR 1.47, 95% 
CI 1.14–1.90). Similar results were observed when the 
analyses additionally controlled for demographic charac-
teristics (adjusted OR 1.51, 95% CI 1.16–1.97). However, 
the significant association between IAC use and all-cause 
mortality disappeared once we controlled for health status 
(adjusted OR 1.32, 95% CI 1.00–1.74). Similar findings 
were noted in model IV, which additionally controlled for 
lifestyle risk factors (adjusted OR 1.26, 95% CI 0.95–1.67, 
Table 3).
Although, not specific to the elderly, it has been reported 
that IAC use is associated with increased risk of fatal and 
nonfatal cardiovascular events,18,19,33,34 suggesting that among 
individuals with cardiovascular disease, IAC use may 
increase the risk of mortality. Therefore, we also included 
an interaction term between IAC use and the presence of 
cardiovascular/metabolic disorder (results not shown). After 
controlling for all the variables included in model IV , there 
was no statistically significant association between the inter-
action term and all-cause mortality (Wald chi-square = 2.676, 
P = 0.102).
Table  2  Description  of  selected  characteristics  according  to 
all-cause mortality among beneficiaries: COPD Medicare Current 
Beneficiary Survey, 2002–2009
wt % Unadjusted logistic 
regression
OR 95% CI Sig
IAC use
  Yes 18.7 1.46 (1.12–1.90) **
  No 13.6
IAC/CMD groups
  IAC and CMD 18.9 1.40 (1.03–1.91) *
  No IAC and CMD 14.3
  IAC and no CMD 17.9 1.26 (0.69–2.28)
  No IAC and no CMD 10.2 0.68 (0.45–1.01)
Health status
  Excellent/very good 7.2
  Good 11.7 1.71 (1.18–2.48) **
  Fair 20.2 3.24 (2.24–4.69) ***
  Poor 29.9 5.69 (3.79–8.53) ***
Gender
  Women 12.8 0.73 (0.58–0.91) **
  Men 16.6
Race/ethnicity
  White 14.2
  African American 16.7 1.11 (0.71–1.72)
  Others 16.2 1.20 (0.86–1.66)
Age, years
  65–69 8.7
  70–74 11.2 1.41 (0.86–2.31)
  $75 18.7 2.53 (1.74–3.69) ***
Notes:  Based  on  2610  elderly  Medicare  beneficiaries  with  COPD,  who  were 
observed between years 2002 and 2009. Asterisks represent significant association 
between inhaled anticholinergic use and beneficiary characteristics based on Chi-
square tests. ***P , 0.001; **0.001  P , 0.01; *0.01  P , 0.05.
Abbreviations: COPD, chronic obstructive pulmonary disease; IAC, inhaled 
anticholinergics;  CMD,  cardiometabolic  disorders  (diabetes,  heart  disease, 
hypertension and stroke); Wt, weighted; CI, confidence interval; OR, odds ratio; 
Sig, significance. 
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Previous studies have shown increased cardiovascular 
events and mortality due to use of IAC.19,33,34 However, in 
a synthesis of available evidence on the safety of IAC use 
in terms of major cardiovascular events, it has been sug-
gested that IAC may not be responsible for severe cardio-
vascular adverse events because of its poor gastrointestinal 
absorption.35 Consistent with this medical opinion, we did 
not find any statistically significant association between the 
interaction term (ie, IAC use and cardiovascular/metabolic 
disorder) and all-cause mortality, suggesting that use of 
IAC is safe in the elderly with cardiovascular disease. Our 
findings are also consistent with a review of the evidence 
from clinical trials on IAC use and cardiovascular-related 
mortality which concluded that IAC is safe.36,37 If repli-
cated, our study findings may have significant implica-
tions for IAC treatment in the elderly with cardiovascular 
conditions.
An interesting observation in our study was the higher 
rate of IAC use among current smokers (22.1%) and former 
smokers (22.8%) compared with nonsmokers (8.5%). It is 
indeed surprising that current smokers were more likely 
to report IAC use compared with nonsmokers and former 
smokers. Current evidence on this issue has consistently 
indicated that, irrespective of smoking status, IAC use is 
associated with improved lung function.38–40 Findings from 
the post hoc analysis of data from the UPLIFT by smoking 
status also suggested that use of tiotropium improves lung 
function and health status, regardless of smoking status.40 
Given these findings, one would expect no differences in 
IAC use by smoking status. However, one could speculate 
that greater IAC use among current smokers could be due 
to some evidence of increased lung function with tiotropium 
in smokers. A study reported by Moita et al indicates that 
the difference in lung function with tiotropium use was 
significantly greater for current smokers as compared with 
former smokers.39
A noteworthy finding from the current study is the 
disappearance of the statistically significant association 
between IAC use and all-cause mortality after adjusting for 
health status. In our study, self-reported perceived health 
status was also a strong predictor of all-cause mortality, 
consistent with prior studies. Prior research using a pooled 
analysis of 22 studies observed a statistically significant 
association between poor health status and increased 
risk of mortality (risk ratio 1.92, 95% CI 1.64–2.25).41 
Further, closer examination of IAC use by health status 
indicates that a higher proportion of elderly individu-
als with poor health status (28.5%) reported using IAC 
compared with those with excellent or very good health 
(12.7%). Therefore, any observed relationship between 
IAC and all-cause mortality may have been driven by 
differences in IAC use according to health status. These 
findings collectively highlight the importance of control-
ling for self-perceived health status when investigating 
the relationship between IAC use and all-cause mortality, 
because adjusting for health status may change the direc-
tion of the relationship between IAC use and mortality, as 
shown in our study.
The strength of this study includes its use of a nationally 
representative sample of elderly individuals over 65 years 
of age, the longitudinal study design, and the ability to 
ascertain the relationship between IAC use and mortality 
after controlling for a comprehensive list of risk factors. 
The study has a few limitations which should be noted. 
Because the MCBS data do not contain precise dates of 
prescription fills, it is difficult to derive data on adherence 
and persistence with IAC, and adherence may affect the 
Table 3 Adjusted odds ratios and 95% confidence intervals from 
multivariable  logistic  regressions  on  all-cause  mortality  among 
elderly beneficiaries with COPD: Medicare Current Beneficiary 
Survey, 2002–2009
Model OR 95% CI Sig
I IAC use
Yes 1.46 (1.12–1.90) **
No
AOR 95% CI Sig
II IAC use
Yes 1.47 (1.14–1.90) **
No
III IAC use
Yes 1.51 (1.16–1.97) **
No
IV IAC use
Yes 1.32 (1.00–1.74)
No
V IAC use
Yes 1.26 (0.95–1.67)
No
Notes:  Based  on  Medicare  beneficiaries  with  COPD,  who  were  observed 
between  years  2002  and  2009.  The  logistic  regression  also  includes  an 
intercept  term  not  presented  here.  Asterisks  represent  significant  group 
differences compared to the reference group based on multivariable logistic 
regressions.  Model  I,  included  IAC  use  as  the  only  independent  variable; 
model II, additionally controlled for all coexisting conditions (mental illness, 
cardiovascular/metabolic  disorders,  musculoskeletal  disorders,  chronic  renal 
failure, and other conditions); model III, controlled for all variables in model II 
and gender, race, age, metro status, education and poverty status; model IV, 
controlled for all variables in model III and perceived health status; and model V, 
controlled for all variables in model IV and body mass index and smoking status. 
**0.001  P , 0.01.
Abbreviations:  COPD,  chronic  obstructive  pulmonary  disease;  IAC,  inhaled 
anticholinergics; OR, odds ratio; AOR, adjusted odds ratios; CI, confidence interval; 
Sig, significance. 
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risk of death. Therefore, studies examining long-term per-
sistence with use of IAC may provide a robust indication 
of the association between IAC use and all-cause mortality. 
The study may also suffer from selection bias as a result of 
unobserved variables, such as patient preferences that may 
have affected IAC use. However, we may have minimized 
any selection bias by controlling for a host of risk factors 
with the potential to impact the association between IAC use 
and all-cause mortality. Further, the MCBS does not collect 
laboratory data, so we were unable to assess and adjust for 
the severity of COPD in our analyses.
Despite these limitations, our study makes a unique con-
tribution to the existing knowledge base on safety of IAC 
use among the elderly. Our results suggest that use of IAC 
may be safe in the elderly with COPD, and indicate a need 
to control for self-perceived health status when examining 
the relationship between IAC use and all-cause mortality. 
Given the lack of evidence related to IAC use and all-cause 
mortality in the elderly population, robust longitudinal stud-
ies are required in this population to derive more definitive 
conclusions.
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